Atlas Trials

Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

Clinical trial NCT04657315 · COMPLETED

Trial details

NCT number
NCT04657315
Sponsor
CHA University
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
GlioblastomaAdult GliosarcomaNeoplasms, BrainNeoplasms, Germ Cell and EmbryonalRecurrent Glioblastoma
Start date
2020-06-24
Primary completion
2022-12-22
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.